Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Leuk Lymphoma. 2014 Nov;55(11):2538–2548. doi: 10.3109/10428194.2014.883073

Figure 5.

Figure 5

(A) Oligonucleotide based aCGH detection of candidate genes RNF145 and EBF1 residing in deleted 5q33.3 locus was found to be associated with AML patients achieving complete remission (27%). These aberrations were not detected in resistant patients. Loss of EBF1 and RNF145 was found to be statistically significant (P<0.05) CR: complete remission. Loss was shown in red. (B) Validation of 7 cases by RT-PCR based copy number analysis showing loses at 5q33.3 in 7 of 7 cases for RNF145 exon 11 and 4 of 7 tested cases for EBF1 exons 1 and 14 whereas 6 cases with no loss at 5q33.3 showed no change for candidate genes EBF1 (exon1 and exon14) and RNF145 (exon 11)